Weithmann K U, Just M, Schlotte V, Seiffge D
Vasa. 1989;18(4):273-6.
Pentoxifylline, Acetylsalicylic acid (ASA) and particularly both drugs in combination are known as active platelet inhibitors in pharmacological models in vivo. However, rather high amounts of these drugs are necessary to demonstrate inhibitory effects on the aggregation of human platelets in vitro, where no vessel walls are present. Surprisingly, these weak effects could be enhanced by the addition of external prostaglandins (prostacyclin (PGI2) and prostaglandin E1 (PGE1] into the in vitro system. Ternary combinations consisting of pentoxifylline, ASA and PGI2 exhibited the most impressive synergistic effects. Thus our study highlights the contribution of prostaglandins, especially of the natural vascular platelet inhibitor PGI2, for the display of the antiaggregatory potency of such drug combinations.
己酮可可碱、乙酰水杨酸（ASA），尤其是这两种药物联合使用时，在体内药理学模型中被认为是活性血小板抑制剂。然而，在体外没有血管壁的情况下，需要相当高剂量的这些药物才能证明对人血小板聚集有抑制作用。令人惊讶的是，通过在体外系统中添加外源性前列腺素（前列环素（PGI2）和前列腺素E1（PGE1）），这些微弱的作用可以得到增强。由己酮可可碱、ASA和PGI2组成的三元组合表现出最显著的协同作用。因此，我们的研究强调了前列腺素，尤其是天然血管血小板抑制剂PGI2，对这类药物组合抗聚集效力发挥的作用。
